Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : | NSE Symbol : | ISIN : | Industry : |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
10-Jan-2025	10-Jan-2025	Change in Directors	Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on 10 January 2025 Intimation under Regulation 30 (LODR) - Change in Directorate (Revised) (As Per BSE Announcement Dated on 10.01.2025)
02-Dec-2024	02-Dec-2024	Preferential Issue	Dear Sir, Pursuant to Regulation 30 read with Schedule III, Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on 2nd December, 2024, has approved the subscription to 48,00,000 convertible warrants ('Warrants') issued by Caprihans India Limited ('Subsidiary').
06-Nov-2024	13-Nov-2024	Quarterly Results	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Un-Audited Financial Results for the quarter and half year ended September 30 2024. Enclosed herewith the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year Ended 30th September 2024, along with Limited Review Report of Statutory Auditor thereon. (As Per Bse Announcement Dated on 13.11.2024)
04-Sep-2024	04-Sep-2024	AGM	Outcome of Board Meeting
08-Aug-2024	14-Aug-2024	Quarterly Results	Quarterly Results Approval for Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2024 and Appointment of Ms. Alka Sagar as an Additional Independent Director. (As Per BSE Announcement dated on 14.08.2024)
10-Jul-2024	10-Jul-2024	Change in Directors	Outcome of Board Meeting
17-May-2024	27-May-2024	Accounts	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve Board Meeting Intimation for Inter-Alia To Consider And Take On Record The Audited Financial Result (Standalone & Consolidated) For The Quarter And Year Ended 31st March 2024. Submission of Audited Financial Results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter and year ended 31 March 2024. (As Per BSE Announcement dated on 27.05.2024) Submission of Audited Financial Results under Regulation 33 of SEBI (LODR) 2015 for the quarter & year ended 31st March, 2024 Board of Directors has not recommended any dividend for the year ended 31 March 2024. We further inform that during the year, the Company incorporated a wholly owned subsidiary 'Bilcare Pharma Solutions Limited (As Per BSE Announcement Dated on 28.05.2024)
26-Feb-2024	26-Feb-2024	Change in Directors	Pursuant to Regulation 30 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors, at their meeting held today i.e. Monday, February 26, 2024, have inter-alia considered, recommended and approved Notice of Postal Ballot and other related agenda items.
05-Feb-2024	13-Feb-2024	Quarterly Results	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve The Unaudited Financial Result (Standalone & Consolidated) for the Quarter and Nine Months ended 31st December 2023. Unaudited Financial Results for the Quarter & Nine Months ended 31st December, 2023 (As Per BSE Announcement dated on 13.02.2024)
31-Jan-2024	31-Jan-2024	Change in Other Executives	Appointment of Company Secretary & Compliance Officer
29-Dec-2023	29-Dec-2023	Change in Directors	Announcement under Regulation 30 (LODR) - Change in Directorate
03-Nov-2023	10-Nov-2023	Quarterly Results	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Unaudited Financial Results (Standalone & Consolidated) for the quarter & half year ended 30th September 2023 Enclosed herewith the Unaudited Financial Results (Standalone and Consolidated) for the Quarter & Half Year ended 30th September, 2023 along with Limited Review Report of Statutory Auditor thereon Unaudited Financial Results (Standalone and Consolidated) for the Quarter & Half year ended 30th September 2023 together with the Limited Review Report of the Statutory Auditor thereon. (As Per BSE Announcement Dated on 10/11/2023)
06-Sep-2023	06-Sep-2023	AGM	Outcome of Board Meeting of the Company and Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Announcement under Regulation 30 (LODR)-Recommendation for Appointment of Statutory Auditors Announcement under Regulation 30 (LODR) - Appointment of Ms. Kavita Bhansali (DIN 05355200) as an Executive Director Announcement under Regulation 30 (LODR)-Appointment of Ms. Deepa Mathur as Chief Financial Officer of the Company
07-Aug-2023	14-Aug-2023	Quarterly Results	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve the Unaudited Financial Result (Standalone & Consolidated) for the quarter ended 30th June 2023. Further to our letter dated August 07, 2023 and pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We wish to inform you that the Board of Directors in its meeting held today i.e. on August 14, 2023 has considered and approved the following: 1. Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended 30th June 2023 together with the Limited Review Report of the Statutory Auditor thereon. 2. Appointment of Ms. Kavita Bhansali (DIN: 05355200) as Non-Executive Non- Independent Director (Additional Director) with effect from 14th August, 2023, subject to the approval of Shareholder at the ensuing Annual General Meeting. Unaudited Financial Results (Standalone & Consolidated) for the Quarter Ended 30-06-2023 (As Per BSE Announcement Dated on 15/08/2023)
24-May-2023	30-May-2023	Accounts	BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Notice is hereby given that the meeting of the Board of Directors of the Company is scheduled to be held on 30th May 2023 inter alia to consider and take on record the Audited Financial Result (Standalone & Consolidated) for the Quarter and Year ended 31st March 2023

1 2 3